Image source: © 2025 Krish Capital Pty. Ltd.

Highlights

  • Berenberg reiterates Buy rating with a target price of AUD 6.88, indicating nearly 18% upside.

  • Panmure Liberum maintains Buy rating with a higher target price of AUD 7.17, reflecting about 23% potential growth.

  • The positive outlook might follows Chesnara’s interim results and strategic progress, including the planned acquisition of HSBC Life (UK).

Chesnara PLC (LSE:CSN), the UK-listed life and health insurance group, has received reaffirmed Buy ratings from two leading investment houses—Berenberg and Panmure Liberum.

According to the latest recommendations, Berenberg analyst Michael Huttner reiterated a Buy rating on 5 September 2025, setting a price target of AUD 6.88, representing an estimated 17.88% upside from the current market price. Similarly, Panmure Liberum analyst Abid Hussain also reaffirmed a Buy stance on 28 June 2024, with a target price of AUD 7.17, implying approximately 22.97% potential growth.

Financial and Strategic Backdrop

Chesnara recently released 2025 interim results, which underscored cash generation, capital position, and ongoing dividend growth.

  • Cash Generation increased 26% to £37 million in the first half of 2025, compared to £29 million in the prior year.

  • Solvency Coverage Ratio rose to 207% (FY 2024: 203%), providing the insurer with significant financial flexibility for mergers and acquisitions.

  • The group declared a 3% increase in its interim dividend to 7.70 pence per share, marking over 20 years of uninterrupted dividend growth.

Strategically, Chesnara announced in July the transformational acquisition of HSBC Life (UK) Ltd, which is expected to generate incremental lifetime cash generation exceeding £800 million, more than three times the £260 million consideration. The transaction was supported by a successful £140 million rights issue and a £150 million Restricted Tier 1 (RT1) bond issuance.

In addition, the group recently secured entry into the FTSE 250 Index and completed the legal merger of its Dutch businesses.

Analyst Perspectives

Berenberg and Panmure Liberum’s reaffirmed Buy ratings reflect market confidence in Chesnara’s ability to sustain shareholder returns while pursuing growth through acquisitions.

With target prices ranging between AUD 6.88 and AUD 7.17, the ratings suggest that Chesnara shares may deliver double-digit upside relative to current levels.